Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Audio By Carbonatix

HAYWARD, Calif.--(BUSINESS WIRE)--Jan 6, 2026--

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that late-breaking data from the nPulse Cardiac Catheter Ablation System first-in-human feasibility study in Europe has been accepted for presentation at the 31 st Annual AF Symposium 2026 meeting in February.

This late breaking data will be presented by Vivek Reddy, MD, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital, NY, and include 6-month and 12-month follow-up data from the nPulse Cardiac Catheter Ablation System first-in-human feasibility study conducted in Europe. The Company plans to provide specifics on presentation times in late January.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260106087962/en/

CONTACT: Investors:

Pulse Biosciences, Inc.

Jon Skinner, CFO

[email protected] Group

Philip Trip Taylor

415.937.5406

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES TECHNOLOGY HEALTH TECHNOLOGY NANOTECHNOLOGY CARDIOLOGY BIOTECHNOLOGY

SOURCE: Pulse Biosciences, Inc.

Copyright Business Wire 2026.

PUB: 01/06/2026 07:00 AM/DISC: 01/06/2026 07:00 AM

http://www.businesswire.com/news/home/20260106087962/en